MRSA血流感染序贯口服与肠外门诊抗菌治疗比较
单中心回顾性队列纳入2008—2018年492例成人MRSA血流感染患者(口服门诊抗菌治疗70例、肠外门诊抗菌治疗422例),经逆概率治疗加权调整后,口服组90天临床失败率无显著降低(aHR 0.379,95%CI 0.131-1.101),90天再入院率显著降低(aHR 0.603,95%CI 0.388-0.937)。
要点
- 经IPTW调整后,口服组90天临床失败率较肠外组无显著差异(aHR 0.379,95%CI 0.131-1.101)。
- 口服组90天再入院率显著低于肠外组(aHR 0.603,95%CI 0.388-0.937)。
- 按感染复杂度和合并症负担分层的预设亚组结果与主分析一致。
核心结论
- 初步证据提示,经选择的MRSA血流感染患者采用门诊序贯口服抗菌治疗,临床结局至少不劣于门诊肠外抗菌治疗。
- 结果为正在开展和未来的口服抗菌药物治疗MRSA血流感染研究提供支持。
研究设计与样本
- 单中心、回顾性队列研究,时间范围为2008年至2018年。
- 共纳入492例成人MRSA血流感染患者,其中口服门诊抗菌治疗(OOAT)70例、门诊肠外抗菌治疗(OPAT)422例。
- 采用逆概率治疗加权(IPTW)调整混杂因素。
主要发现
- IPTW调整后,口服组90天临床失败率较肠外组无显著降低(aHR 0.379,95%CI 0.131-1.101)。
- 口服组90天再入院率显著低于肠外组(aHR 0.603,95%CI 0.388-0.937)。
- 按索引感染复杂度和合并症负担定义的预设亚组分析结果与主分析一致。
- 口服组患者总体特征符合不良结局风险较低,但IPTW后关键预后因素已均衡。
关键数值与推荐
- 主要结局为90天临床失败,包括MRSA血流感染复发、深部MRSA感染或全因死亡。
- 90天临床失败:aHR 0.379(95%CI 0.131-1.101)。
- 90天再入院:aHR 0.603(95%CI 0.388-0.937)。
临床怎么用
- 对经选择的MRSA血流感染成人,完成静脉治疗后门诊序贯口服抗菌治疗或可作为一种选择。
- 该策略可能降低90天再入院率,但临床失败率获益尚无统计学显著性。
- 应用前需结合感染复杂度与合并症负担评估患者是否属于适宜选择人群。
局限性
- 单中心回顾性设计,存在选择偏倚可能。
- 口服组样本量较小(70例),且基线特征总体提示不良结局风险较低。
- 90天临床失败率的降低无统计学显著性,证据仅为初步性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Published guidelines call for prolonged courses of intravenous (iv) antibiotics for the treatment of MRSA bloodstream infection (BSI) to ensure eradication of deep foci and decrease relapse risk. Sequential iv-to-oral antibiotic therapy has been successfully applied to other serious infections but has not been evaluated for MRSA BSI. OBJECTIVES: To compare outcomes in adults completing MRSA BSI therapy with oral versus parenteral antibiotics in the outpatient setting [oral outpatient antibiotic therapy (OOAT) versus outpatient parenteral antibiotic therapy (OPAT)]. METHODS: This was a single-centre, retrospective, cohort study between 2008 and 2018. The primary outcome was 90 day clinical failure (MRSA BSI recurrence, deep-seated MRSA infection or all-cause mortality). Analyses were adjusted for confounding using inverse probability of treatment weighting (IPTW). RESULTS: A total of 492 patients were included (70 OOAT, 422 OPAT). In general, OOAT patients had characteristics consistent with a lower risk of poor outcomes; however, after IPTW key prognostic factors were balanced. In IPTW-adjusted analysis, there was non-significant reduction in the rate of 90 day clinical failure in the OOAT group compared with the OPAT group [adjusted HR (aHR) 0.379, 95% CI 0.131-1.101]. In analyses restricted to pre-specified subgroups defined by index infection complexity and comorbidity burden, findings were consistent with the main analysis. Furthermore, OOAT patients had a significantly reduced rate of 90 day hospital readmission (aHR 0.603, 95% CI 0.388-0.937). CONCLUSIONS: We provide preliminary evidence that selected patients with MRSA BSI may have at least equivalent clinical outcomes with OOAT versus OPAT and provide support to ongoing and future studies evaluating oral antibiotics for MRSA BSI.
引用
- Jorgensen SCJ, Lagnf AM, Bhatia S, et al. Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer. J Antimicrob Chemother. 2019. PMID: 30418557. doi:10.1093/jac/dky452
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。